Semax and Selank are the two most prominent Russian-developed neuropeptide drugs, both approved for clinical use in Russia but developed from entirely different parent molecules for different primary indications. Semax, derived from ACTH(4-10), is primarily neuroprotective and nootropic. Selank, derived from tuftsin, is primarily anxiolytic and immunomodulatory. This comparison examines their distinct mechanisms, clinical applications, and research profiles to guide appropriate selection in research contexts.
Origins and Design Philosophy
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was designed as a stable, CNS-penetrating fragment of ACTH that retains neurotrophic activity without adrenocortical stimulation. Its development focused on neuroprotection and cognitive enhancement, driven by the observation that ACTH(4-10) improves attention and memory in animal models.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was designed as a stable derivative of the immune peptide tuftsin that exhibits anxiolytic CNS activity. Its development focused on anxiety reduction without the sedation and dependence of benzodiazepines, leveraging tuftsin’s known effects on both immune and nervous systems.
Both share the C-terminal Pro-Gly-Pro stabilizing tripeptide and are administered intranasally, but their pharmacological profiles diverge substantially from their respective parent molecules.
Primary Mechanisms Compared
| Feature | Semax | Selank |
|---|---|---|
| Parent molecule | ACTH(4-10) | Tuftsin |
| Primary effect | Nootropic/neuroprotective | Anxiolytic/immunomodulatory |
| Key pathway | BDNF/NGF upregulation | GABAergic modulation |
| Neurotransmitter focus | Dopamine, serotonin, acetylcholine | GABA, enkephalins |
| Immune effects | Minimal | Significant (phagocytosis, NK cells, cytokines) |
| Clinical approval | Stroke, cognitive impairment (Russia) | Anxiety disorders (Russia) |
Cognitive Effects
Both peptides improve cognitive performance in animal models, but through different mechanisms. Semax enhances cognition primarily through neurotrophic factor upregulation—BDNF and NGF promote synaptic plasticity, dendritic growth, and LTP in hippocampal circuits. The cognitive effect is direct and robust across multiple memory paradigms.
Selank’s cognitive benefits are partly indirect, mediated through anxiety reduction. Anxiety impairs working memory, attention, and decision-making through prefrontal cortex dysregulation. By normalizing GABAergic tone and reducing anxiety-related interference, Selank enables better cognitive performance, particularly under stressful conditions. Selank also has direct nootropic effects through BDNF modulation, though these are less pronounced than Semax’s neurotrophic effects.
Neuroprotection Profiles
Semax is the stronger neuroprotective agent, with extensive data in ischemic stroke, traumatic brain injury, and neurodegenerative disease models. Its mechanisms include excitotoxicity reduction, antioxidant enzyme upregulation, and anti-apoptotic signaling through the CREB/BDNF pathway. Selank provides neuroprotection primarily through anti-inflammatory mechanisms and oxidative stress reduction, but has less stroke and TBI-specific data.
Anxiety and Mood
Selank is clearly superior for anxiety research. Its GABAergic and enkephalinergic mechanisms provide anxiolytic effects without sedation, cognitive impairment, or dependence. Semax has mild anxiolytic properties through serotonergic modulation but is not primarily an anxiolytic agent. For research specifically targeting anxiety, Selank is the appropriate choice.
Combination Rationale
The complementary profiles of Semax and Selank have led some researchers to investigate concurrent use. The rationale is that Semax provides neurotrophic and cognitive support while Selank provides anxiolytic and immune support—addressing different dimensions of neurological well-being. However, controlled combination studies are limited, and interactions between the two peptides’ signaling pathways have not been fully characterized.
Frequently Asked Questions
Should researchers choose Semax or Selank?
Semax for neuroprotection and cognition research; Selank for anxiety and neuro-immune research. They target complementary pathways.
Can they be used together in research?
Some researchers study both given complementary mechanisms, but formal combination studies are limited.
Which has more clinical evidence?
Both are approved in Russia. Semax has more neurological data (stroke); Selank has more psychiatric data (anxiety). Neither has Western clinical trial data.